NCT05798819View on ClinicalTrials.gov

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

December 1, 2026

Conditions
Persistent, Recurrent, or Metastatic Cervical Cancer
Interventions
DRUG

GLS-010

IV infusion

DRUG

Placebo

IV infusion

DRUG

paclitaxel

IV infusion

DRUG

cisplatin

IV infusion

DRUG

carboplatin

IV infusion

DRUG

bevacizumab

IV infusion

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Hospital, Shanghai

All Listed Sponsors
lead

Guangzhou Gloria Biosciences Co., Ltd.

INDUSTRY

NCT05798819 - A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter